Program Agenda

The Resident Education Program aims to provide early-stage adult and pediatric neurology residents (and other residency programs) with a foundation in headache medicine education led by experienced faculty in neurologic education and headache medicine.

We hope that this program will inspire a greater number of junior neurology trainees to consider pursuing careers in headache medicine.


This fall, the American Headache Society’s Resident Education Program will be held in-person starting the evening of Friday, October 13 through the morning of Sunday, October 15, 2023 in Los Angeles, CA.

Faculty and residents will engage throughout the meeting in an interactive format that features lectures, small group sessions and workshops, and a friendly competition, as well as informally at combined faculty-resident meals and social events.

The Resident Education Program will:

  • Provide early stage adult and pediatric neurology residents with a foundation in headache medicine education.
  • Promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders.
  • Introduce residents to experienced faculty in neurologic education and headache medicine.
  • Inspire a greater number of neurology residents to pursue careers in headache medicine.

Residents who participate in the Resident Education Program will be prepared to:

  • Diagnose and manage patients consulting for headache conditions, including the evidence-based use of pharmacologic, nonpharmacologic, procedural, and behavioral approaches
  • Differentiate where and how new therapies augment and improve the current standard of care in the acute and preventive treatment of migraine and other headache disorders
  • Engage in scholarly activity about migraine (e.g. teaching, research)


The AHS actively monitors the health and safety guidance from the Centers for Disease Control as well as state and local health departments. We want attendees to enjoy a safe environment at all AHS meetings. While the AHS continues to recommend people are up to date on COVID-19 vaccination, attendees of AHS meetings are not required to be vaccinated or verify vaccination status. In addition, masks are optional for AHS meetings and prior antigen testing is not required. We will continue to follow best practices recommended by the Centers for Disease Control and Prevention and abide by any legal mandates and recommendations from government officials in the location of any AHS meeting. These protocols and information are subject to change.

Please note, even with safeguards and the AHS’s overarching commitment to attendee wellness, there remains a risk of contracting COVID-19.

Program Committee

Matthew S. Robbins, MD, FAHS, Chair
Weill Cornell Medical College
New York, NY

Deborah I. Friedman, MD, MPH, FAHS
UT Southwestern
Dallas, TX

Amy Gelfand, MD, MAS, FAHS
University of California San Francisco
San Francisco, CA

Peter J. Goadsby, MD, PhD, FAHS
University of California, Los Angeles
Los Angeles, CA

Melissa Rayhill, MD, FAHS
University at Buffalo Jacobs School of Medicine, The State University of New York
Williamsville, NY

Noah Rosen, MD, FAHS
Donald and Barbara Zucker School of Medicine Northwell Headache Center
Great Neck, NY

Niushen Zhang, MD, FAHS
Stanford University
Palo Alto, CA



2023 Resident Education Program Agenda*

*Subject to change


Application Criteria: 

  • Submit the online application form with the following supporting documents:
    • Completion of brief statement of interest (100-200 words)
    • CV
    • Letter of support from Program Director
      • Each program director may nominate only one early stage resident from their program (PGY1 or PGY2 for adult neurology, PGY1, PGY2, or PGY3 for child neurology, but if no such candidate is available a PGY3 adult neurology or PGY4 child neurology resident would be considered).
  • Applicant must be a resident in a US adult or pediatric neurology training program. We will also consider applications from trainees in other residency programs, including but not limited to internal medicine, family medicine, pediatrics, physiatry, obstetrics and gynecology, and orofacial pain. International applications are not eligible at this time.

Accepted participants will receive the following:

  • Reimbursement up to $1,500 for eligible travel expenses including:
    • Roundtrip coach/economy class travel
    • Ground transportation to/from airport and conference center (car rental and gas not covered)
    • Two nights’ accommodation at the conference hotel
  • Meals, which are included in the meeting, from Friday night through Sunday morning.
  • Complimentary one-year trainee membership to the American Headache Society or extension of an existing AHS Trainee membership

Application Timeline:

  • Monday, July 3: Applications open
  • Sunday, August 13: Applications due
  • On or about Monday, August 28: Final decisions to be distributed

The American Headache Society gratefully acknowledges the support of the 2023 Resident Education Program from our industry supporters:


We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, is tirelessly dedicated to restoring brain health, so every person can be their best. Lundbeck has a long heritage of innovation in neuroscience and is focused on delivering transformative treatments that address unmet needs in brain health.


The American Headache Society gratefully acknowledges the educational grant support of the 2023 Resident Education Program from our industry supporters:

AbbVie, Inc.
Eli Lilly and Company
Lundbeck LLC
Pfizer Inc.